• 1
    Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:6238.
  • 2
    De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:33346.
  • 3
    Gillis S, Crabtree GR, Smith KA. Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979; 123:162431.
  • 4
    Ho S, Clipstone N, Timmermann L et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80 (3 Part 2):S405.
  • 5
    Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483510.
  • 6
    Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17:6814.
  • 7
    Jolivet J, Schilsky RL, Bailey BD, Chabner BA. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann NY Acad Sci 1982; 397:18492.
  • 8
    Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 1995; 330:11581.
  • 9
    Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJ. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337:1814.
  • 10
    Kawabe Y, Ochi A. Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 1991; 349:2458.
  • 11
    Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998; 17:326170.
  • 12
    Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5:62530.
  • 13
    Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1. Nature 1995; 373:43841.
  • 14
    Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16:56974.
  • 15
    Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268:13479.
  • 16
    Reap EA, Leslie D, Abrahams M, Eisenberg RA, Cohen PL. Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice. J Immunol 1995; 154:93643.
  • 17
    Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284:5556.
  • 18
    Zacharchuk CM, Mercep M, Chakraborti PK, Simons SSJr, Ashwell JD. Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. J Immunol 1990; 145: 403745.
  • 19
    Kato GJ, Quddus FF, Shuster JJ et al. High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 1993; 82:23049.
  • 20
    Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:5747.
  • 21
    Müller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:40313.
  • 22
    Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:3228.
  • 23
    Wang GJ, Cai L. Relatively low-dose cyclophosphamide is likely to induce apoptotic cell death in rat thymus through Fas/Fas ligand pathway. Mutat Res 1999; 427:12533.
  • 24
    Yang Y, Mercep M, Ware CF, Ashwell JD. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med 1995; 181:167382.
  • 25
    Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int Immunol 1996; 8:101726.
  • 26
    Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5:13037.
  • 27
    Hochman JH, Shimizu Y, DeMars R, Edidin M. Specific associations of fluorescent beta-2-microglobulin with cell surfaces. The affinity of different H-2 and HLA antigens for beta-2-microglobulin. J Immunol 1988; 140:23229.
  • 28
    Zemmour J, Little AM, Schendel DJ, Parham P. The HLA-A,B ‘negative’ mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992; 148:19418.
  • 29
    Van Pel A, De Plaen E, Boon T. Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell Mol Genet 1985; 11:46775.
  • 30
    Girdlestone J. Nucleotide sequence of an HLA-A1 gene. Nucleic Acids Res 1990; 18:6701.
  • 31
    Gussow D, Rein R, Ginjaar I et al. The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 1987; 139:31328.
  • 32
    Gunning P, Leavitt J, Muscat G, Ng SY, Kedes L. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA 1987; 84:48315.
  • 33
    Trauth BC, Klas C, Peters AM et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:3015.
  • 34
    Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139:2719.
  • 35
    Pezzutto A, Dorken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 1987; 138:27939.
  • 36
    Carrera AC, Sanchez-Madrid F, Lopez-Botet M, Bernabeu C, De Landazuri MO. Involvement of the CD4 molecule in a post-activation event on T cell proliferation. Eur J Immunol 1987; 17:17986.
  • 37
    Hoffman RA, Kung PC, Hansen WP, Goldstein G. Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci USA 1980; 77:49147.
  • 38
    Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM. Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor. Mol Cell Endocrinol 1997; 136:238.
  • 39
    Posovszky C, Friesen C, Herr I, Debatin KM. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia 1999; 13:4009.
  • 40
    Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377:34851.
  • 41
    Lanza L, Scudeletti M, Puppo F et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 1996; 103:48290.
  • 42
    Brunetti M, Martelli N, Colasante A, Piantelli M, Musiani P, Aiello FB. Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes. Blood 1995; 86:4199205.
  • 43
    Eto M, Mayumi H, Tomita Y et al. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol 1991; 146:14029.
  • 44
    Maeda T, Eto M, Nishimura Y, Nomoto K, Kong YY, Nomoto K. Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. Immunology 1993; 78:11321.
  • 45
    Martinez-Lorenzo MJ, Alava MA, Anel A, Pineiro A, Naval J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996; 89:5117.
  • 46
    Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181:717.
  • 47
    Martinez-Lorenzo MJ, Alava MA, Gamen S et al. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998; 28:271425.
  • 48
    Makrigiannis AP, Hoskin DW. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity. J Immunol 1997; 159:47007.
  • 49
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:1298302.DOI: 10.1038/15256
  • 50
    Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329:122530.
  • 51
    Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:72935.
  • 52
    Aschan J, Carlens S, Hagglund H et al. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. Clin Transplant 1999; 13:5129.
  • 53
    Daikh DI, Wofsy D. Cutting edge. reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166:29136.
  • 54
    Eto M, Nishimura Y, Matsuo K et al. Prolongation of kidney graft survival by cyclophosphamide-induced tolerance in rats. J Urol 1995; 153:16936.
  • 55
    Okano S, Eto M, Tomita Y et al. Cyclophosphamide-induced tolerance in rat orthotopic liver transplantation. Transplantation 2001; 71: 44756.